<bill session="109" type="h" number="4429" updated="2023-01-13T04:49:38Z">
  <state datetime="2005-11-18">REFERRED</state>
  <status>
    <introduced datetime="2005-11-18"/>
  </status>
  <introduced datetime="2005-11-18"/>
  <titles>
    <title type="display">Food and Drug Administration Safety Act of 2005</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes.</title>
    <title type="short" as="introduced">Food and Drug Administration Safety Act of 2005</title>
  </titles>
  <sponsor bioguide_id="T000266"/>
  <cosponsors>
    <cosponsor bioguide_id="K000336" joined="2006-09-07"/>
    <cosponsor bioguide_id="M000404" joined="2006-05-09"/>
    <cosponsor bioguide_id="R000033" joined="2005-11-18"/>
  </cosponsors>
  <actions>
    <action datetime="2005-11-18">
      <text>Introduced in House</text>
    </action>
    <action datetime="2005-11-18" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2005-12-02">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="109" type="s" number="930" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative remedies"/>
    <term name="Advertising"/>
    <term name="Biomedical engineering"/>
    <term name="Clinical trials"/>
    <term name="Commerce"/>
    <term name="Congress"/>
    <term name="Congressional reporting requirements"/>
    <term name="Consumer education"/>
    <term name="Cost effectiveness"/>
    <term name="Data banks"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug adulteration"/>
    <term name="Drug approvals"/>
    <term name="Drug industry"/>
    <term name="Epidemiology"/>
    <term name="Executive reorganization"/>
    <term name="Federal advisory bodies"/>
    <term name="Finance and Financial Sector"/>
    <term name="Fines (Penalties)"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Government Operations and Politics"/>
    <term name="Government paperwork"/>
    <term name="Government publicity"/>
    <term name="Health information systems"/>
    <term name="Law"/>
    <term name="Licenses"/>
    <term name="Medical supplies"/>
    <term name="Pharmaceutical research"/>
    <term name="Product safety"/>
    <term name="Risk"/>
    <term name="Sales promotion"/>
    <term name="Science, Technology, Communications"/>
  </subjects>
  <amendments/>
  <summary date="2005-12-22T14:43:24Z" status="Introduced in House">Food and Drug Administration Safety Act of 2005 - Amends the Federal Food, Drug, and Cosmetic Act to establish the Center for Postmarket Drug Evaluation and Research within the Food and Drug Administration (FDA).

Requires the Director of the Center to conduct activities to ensure the safety and effectiveness of FDA-approved drugs and licensed biological products, including by: (1) conducting postmarket risk assessment and surveillance of such drugs and products; (2) determining whether a postmarket study is required; (3) contracting, or requiring the sponsor of such a drug or product to contract, with the holders of domestic and international surveillance databases to conduct epidemiologic and other observational studies; (4) determining whether a drug or product may present an unreasonable risk to the health of patients or the general public; (5) taking corrective action if such an unreasonable risk may exist; and (6) making information about the safety and effectiveness of such drugs and biological products available to the public and health care providers in a timely manner.

Requires the Drug Safety and Risk Management Drug Advisory Committee to make recommendations to the Director on postmarket studies, drugs and biological products that may present an unreasonable risk, and appropriate corrective actions.

Allows the Secretary of Health and Human Services to assess civil penalties for violations of this Act.

Allows the Director to withdraw or suspend approval of a drug or license for a biological product using expedited procedures under certain circumstances.

Transfers to the Center the functions and duties of the Office of Drug Safety.</summary>
</bill>
